Research Paper Volume 13, Issue 11 pp 15444—15458
Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas
Figure 4. Immune phenotype and survival analysis. The immuno-phenotype showed higher CD274 and TMB (A) in the tumor with altered RTK/Ras/PI3K/AKT signaling with different survival outcome (B). CD274 and CD8+ T cells (C) were significantly higher in activated RTK/Ras/PI3K/AKT pathway, with difference in OS (D).